CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...
Phase 3
Ann Arbor, Michigan, United States and 250 other locations
doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated d...
Phase 1
Detroit, Michigan, United States and 3 other locations
To confirm the safety and performance of the da Vinci SP Surgical System, Instruments and Accessories in a complex colorectal procedure such as low a...
Detroit, Michigan, United States and 8 other locations
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor ...
Phase 1, Phase 2
Ann Arbor, Michigan, United States and 83 other locations
This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors....
Phase 1
Detroit, Michigan, United States and 53 other locations
This study will test the safety of a drug called SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects ...
Phase 1
Detroit, Michigan, United States and 12 other locations
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor...
Phase 2, Phase 3
Ann Arbor, Michigan, United States and 904 other locations
aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 inhibitor agent can decrease tumor...
Phase 1, Phase 2
Detroit, Michigan, United States and 13 other locations
tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors...
Phase 1
Detroit, Michigan, United States and 11 other locations
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody ta...
Phase 1
Ann Arbor, Michigan, United States and 33 other locations
Clinical trials
Research sites
Resources
Legal